» Articles » PMID: 3435106

In Vitro Activity of Sulfonamides and Sulfones Against Leishmania Major Promastigotes

Overview
Specialty Pharmacology
Date 1987 Oct 1
PMID 3435106
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

We examined the susceptibility of promastigotes of Leishmania major to sulfonamides and sulfones in vitro. In a completely defined medium only sulfamoxole, sulfaquinoxaline, and dapsone were inhibitory; the concentrations required for 50% inhibition of the rate of growth were 150, 600, and 600 microM, respectively. Eleven other sulfa drugs were ineffective at concentrations up to 2 mM. The growth inhibition was similar to that observed in procaryotes: the cells continued logarithmic growth for several cell doublings before inhibition was observed. Surprisingly, the addition of p-aminobenzoate or folate did not reverse the effects of the active sulfa drugs, the effects of sulfamoxole and methotrexate were additive rather than synergistic, and the addition of thymidine reversed methotrexate but not sulfa-drug inhibition. These results suggest that the mode of action of sulfa drugs on L. major is not by the classical route of inhibition of de novo folate synthesis. Promastigotes could be propagated for more than 40 passages in a completely defined medium in which the only added pterin was biopterin. The folate concentration in this medium was less than 10(-10) to 10(-11) M, as determined by a Leishmania bioassay. Although these data suggest that L. major may be capable of de novo synthesis of folate, the nonclassical mode of action of sulfa drugs, as well as other studies, favors the view that L. major is auxotrophic for folate.

Citing Articles

Sulfonamides as Inhibitors of - Potential New Treatments for Leishmaniasis.

Katinas J, Epplin R, Hamaker C, Jones M Antiinfect Agents. 2018; 15(1):57-62.

PMID: 29399442 PMC: 5748876. DOI: 10.2174/2211352515666170216143401.


N-(4-Meth-oxy-2-nitro-phen-yl)-N-(methyl-sulfon-yl)methane-sulfonamide.

Yousuf S, Siddiqui H, Farooq R, Choudhary M Acta Crystallogr Sect E Struct Rep Online. 2012; 68(Pt 7):o2090.

PMID: 22798770 PMC: 3393905. DOI: 10.1107/S160053681202483X.


Folate metabolic pathways in Leishmania.

Vickers T, Beverley S Essays Biochem. 2011; 51:63-80.

PMID: 22023442 PMC: 3278214. DOI: 10.1042/bse0510063.


Phenylalanine hydroxylase (PAH) from the lower eukaryote Leishmania major.

Lye L, Kang S, Nosanchuk J, Casadevall A, Beverley S Mol Biochem Parasitol. 2010; 175(1):58-67.

PMID: 20887755 PMC: 2987234. DOI: 10.1016/j.molbiopara.2010.09.004.


Increased transport of pteridines compensates for mutations in the high affinity folate transporter and contributes to methotrexate resistance in the protozoan parasite Leishmania tarentolae.

Kundig C, Haimeur A, Legare D, Papadopoulou B, Ouellette M EMBO J. 1999; 18(9):2342-51.

PMID: 10228149 PMC: 1171317. DOI: 10.1093/emboj/18.9.2342.


References
1.
KIDDER G, DEWEY V, Rembold H . The origin of unconjugated pteridines in Crithidia fasciculata. Arch Mikrobiol. 1967; 59(1):180-4. DOI: 10.1007/BF00406330. View

2.
Kandil E . Treatment of cutaneous leishmaniasis with trimethoprim-sulfamethoxazole combination. Dermatologica. 1973; 146(5):303-9. DOI: 10.1159/000251981. View

3.
Mattock N, Peters W . The experimental chemotherapy of leishmaniasis. II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use. Ann Trop Med Parasitol. 1975; 69(3):359-71. View

4.
David M, FEUERMAN E . [Cutaneous leishmaniasis treated with trimethoprim-sulfamethoxasol]. Harefuah. 1977; 92(7):305-7. View

5.
Murphy K, Bong A . Co-trimoxazole for systemic leishmaniasis. Lancet. 1981; 1(8215):323-4. DOI: 10.1016/s0140-6736(81)91929-2. View